SQZ Biotechnologies (SQZB) Form 3 SQZ Biotechnologies / Klavs F. Jensen ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Jensen Klavs F.

(Last) (First) (Middle)

200 ARSENAL YARDS BLVD, SUITE 210

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2020

3. Issuer Name and Ticker or Trading Symbol
SQZ Biotechnologies Co [ SQZ ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	324,320	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series Seed Convertible Preferred Stock	(1)	(1)	Common Stock	7,388	(1)	D
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	7,274	(1)	D
Stock Option	(2)	03/04/2028	Common Stock	824	2.02	D
Stock Option	(3)	02/18/2029	Common Stock	1,536	4.59	D

Explanation of Responses:

1. The Issuer's preferred stock is convertible into common stock on a 1.053 for 1 basis at the holder's election and will automatically convert upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

2. This option was originally granted for 2,632 shares underlying the option grant. The option vested and became exercisable as to 25% of the original grant amount on January 23, 2019 and in 36 equal monthly installments thereafter.

3. This option was originally granted for 2,632 shares underlying the option grant. The option vested and became exercisable as to 25% of the underlying securities on February 1, 2020 and in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Lawrence Knopf, Attorney-in-Fact for Klavs F. Jensen	10/29/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.